Trofosfamide

Trofosfamide
Clinical data
Trade names	Ixoten
AHFS/Drugs.com	International Drug Names
Routes of; administration	By mouth (film-coated tablets)
ATC code	L01AA07 (WHO) ;
Legal status
Legal status	DE: § 48 AMG/§ 1 MPAV (Prescription only);
Identifiers
	IUPAC name N,N,3-tris(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amide 2-oxide;
CAS Number	22089-22-1 ;
PubChem CID	65702;
ChemSpider	59129 ;
UNII	H64JRU6GJ0;
KEGG	D07252 ;
ChEMBL	ChEMBL462019 ;
CompTox Dashboard (EPA)	DTXSID60865031 ;
ECHA InfoCard	100.040.686
Chemical and physical data
Formula	C9H18Cl3N2O2P
Molar mass	323.58 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CN(P(=O)(OC1)N(CCCl)CCCl)CCCl;
	InChI InChI=1S/C9H18Cl3N2O2P/c10-2-6-13-5-1-9-16-17(13,15)14(7-3-11)8-4-12/h1-9H2 ; Key:UMKFEPPTGMDVMI-UHFFFAOYSA-N ;
	(what is this?) (verify)

Trofosfamide (INN) is a nitrogen mustard alkylating agent. It is sometimes abbreviated "TRO".^[1] It has been used in trials to study its effects on ependymoma, medulloblastoma, sarcoma, soft tissue, supratentorial PNET, and recurrent brain tumors.^[2]

References

^ Jahnke K, Thiel E, Bechrakis NE, et al. (December 2008). "Ifosfamide or trofosfamide in patients with intraocular lymphoma". J. Neurooncol. 93 (2): 213–7. doi:10.1007/s11060-008-9761-8. PMID 19099202. S2CID 33892177.
^ "Trofosfamide". www.drugbank.ca. Retrieved 2019-12-19.